Jack Anders - Sep 1, 2023 Form 4 Insider Report for Revolution Medicines, Inc. (RVMD)

Signature
/s/ Jack Anders
Stock symbol
RVMD
Transactions as of
Sep 1, 2023
Transactions value $
-$647,492
Form type
4
Date filed
9/6/2023, 08:02 PM
Previous filing
Jun 22, 2023
Next filing
Sep 20, 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction RVMD Common Stock Options Exercise $53.6K +20K +36.3% $2.68* 75.1K Sep 1, 2023 Direct F1, F2
transaction RVMD Common Stock Sale -$701K -20K -26.63% $35.05 55.1K Sep 1, 2023 Direct F1, F2, F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction RVMD Stock Option (Right to Buy) Options Exercise $0 -20K -32.15% $0.00 42.2K Sep 1, 2023 Common Stock 20K $2.68 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person adopted on March 27, 2023.
F2 Includes 44,276 restricted stock units.
F3 This transaction was executed in multiple trades in prices ranging from $35.00 to $35.24, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.